Researchers from the University of British Columbia have identified a new set of mutations that make tumor cells vulnerable to Poly(ADP-ribose) polymerase, or PARP, inhibitors. The genes in question, for cohesins, join BRCA and RAD51D as possible biomarkers for tumors that are sensitive to PARP inhibitors.